연구성과로 돌아가기
2020 연구성과별 연구자 정보 (1204 / 2428)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Marrone, Kristen A. | Marrone, KA | 14 | Johns Hopkins Univ, Baltimore, MD USA | dcatenac@bsd.uchicago.edu; | |||||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Kelly, Ronan J. | Kelly, RJ | 15 | Baylor Univ, Med Ctr, Dallas, TX USA | dcatenac@bsd.uchicago.edu; | |||||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Juergens, Rosalyn A. | Juergens, RA | 16 | McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada | 0000-0001-8627-4704 | Juergens, Rosalyn | dcatenac@bsd.uchicago.edu; | |||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Kim, Jong Gwang | Kim, JG | 17 | Kyungpook Natl Univ, Chilgok Hosp, Daegu, South Korea | dcatenac@bsd.uchicago.edu; | |||||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Bendell, Johanna C. | Bendell, JC | 18 | Sarah Cannon Res Inst, Nashville, TN USA | dcatenac@bsd.uchicago.edu; | |||||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Alcindor, Thierry | Alcindor, T | 19 | McGill Univ, Ctr Hlth, Montreal, PQ, Canada | dcatenac@bsd.uchicago.edu; | |||||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Sym, Sun Jin | Sym, SJ | 20 | Gachon Univ, Gil Med Ctr, Incheon, South Korea | dcatenac@bsd.uchicago.edu; | |||||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Song, Eun-Kee | Song, EK | 21 | Chonbuk Natl Univ, Sch Med, Jeonju, South Korea | dcatenac@bsd.uchicago.edu; | |||||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Chee, Cheng Ean | Chee, CE | 22 | Natl Univ Canc Inst, Singapore, Singapore | dcatenac@bsd.uchicago.edu; | |||||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Chao, Yee | Chao, Y | 23 | Taipei Vet Gen Hosp, Taipei, Taiwan | dcatenac@bsd.uchicago.edu; | |||||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Kim, Sunnie | Kim, S | 24 | Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA | J-2750-2012 | Kim, Tae-You | dcatenac@bsd.uchicago.edu; | |||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Kim, Sunnie | Kim, S | 24 | Univ Colorado, Ctr Canc, Aurora, CO USA | J-2750-2012 | Kim, Tae-You | dcatenac@bsd.uchicago.edu; | |||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Lockhart, A. Craig | Lockhart, AC | 25 | Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea | dcatenac@bsd.uchicago.edu; | |||||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Lockhart, A. Craig | Lockhart, AC | 25 | Washington Univ, Sch Med, St Louis, MO USA | dcatenac@bsd.uchicago.edu; | |||||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Lockhart, A. Craig | Lockhart, AC | 25 | Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA | dcatenac@bsd.uchicago.edu; |
페이지 이동: